Mirum Pharmaceuticals, a rare disease company, has entered a definitive agreement to acquire privately held Bluejay Therapeutics, adding worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV). The transaction strengthens Mirum’s rare liver disease portfolio and adds a fourth potential registrational milestone within the next 18 months. Brelovitug is currently […]
